These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 15841896)

  • 1. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design and analysis issues for economic analysis alongside clinical trials.
    Marshall DA; Hux M
    Med Care; 2009 Jul; 47(7 Suppl 1):S14-20. PubMed ID: 19536012
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Conducting economic evaluations alongside multinational clinical trials: toward a research consensus.
    Reed SD; Anstrom KJ; Bakhai A; Briggs AH; Califf RM; Cohen DJ; Drummond MF; Glick HA; Gnanasakthy A; Hlatky MA; O'Brien BJ; Torti FM; Tsiatis AA; Willan AR; Mark DB; Schulman KA
    Am Heart J; 2005 Mar; 149(3):434-43. PubMed ID: 15864231
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analytic considerations in economic evaluations of multinational cardiovascular clinical trials.
    Torti FM; Reed SD; Schulman KA
    Value Health; 2006; 9(5):281-91. PubMed ID: 16961546
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost data for individual patients included in clinical studies: no amount of statistical analysis can compensate for inadequate costing methods.
    Graves N; Walker D; Raine R; Hutchings A; Roberts JA
    Health Econ; 2002 Dec; 11(8):735-9. PubMed ID: 12457373
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How has the impact of 'care pathway technologies' on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect?
    Allen D; Rixson L
    Int J Evid Based Healthc; 2008 Mar; 6(1):78-110. PubMed ID: 21631815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trials and tribulations. Emerging issues in designing economic evaluations alongside clinical trials.
    Coyle D; Davies L; Drummond MF
    Int J Technol Assess Health Care; 1998; 14(1):135-44. PubMed ID: 9509801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Good research practices for cost-effectiveness analysis alongside clinical trials: the ISPOR RCT-CEA Task Force report.
    Ramsey S; Willke R; Briggs A; Brown R; Buxton M; Chawla A; Cook J; Glick H; Liljas B; Petitti D; Reed S
    Value Health; 2005; 8(5):521-33. PubMed ID: 16176491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Design of cluster-randomized trials of quality improvement interventions aimed at medical care providers.
    Glynn RJ; Brookhart MA; Stedman M; Avorn J; Solomon DH
    Med Care; 2007 Oct; 45(10 Supl 2):S38-43. PubMed ID: 17909381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. It is important to note that RWD will never replace the more traditional and more robust RCT data; however, the emerging trend is to incorporate data that are more generalizable. Introduction.
    Mullins CD; Sanchez RJ
    J Manag Care Pharm; 2011; 17(9 Suppl A):S03-4. PubMed ID: 22074667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protocol-driven costs in trial-based pharmacoeconomic analyses.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):673-5. PubMed ID: 22098282
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness as an outcome in randomized clinical trials.
    Hlatky MA; Owens DK; Sanders GD
    Clin Trials; 2006; 3(6):543-51. PubMed ID: 17170039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors to consider when designing phase III clinical trials involving economic evaluations.
    van Enckevort PJ; TenVergert EM; Kingma J; Koëter GH; Rutten FF
    Percept Mot Skills; 1999 Dec; 89(3 Pt 2):1059-72. PubMed ID: 10710753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Health economic evaluations alongside clinical trials: a review of study protocols at the Swedish Medical Products Agency.
    Lindfors A; Feltelius N; Lundkvist J
    Int J Technol Assess Health Care; 2007; 23(3):392-6. PubMed ID: 17579944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Literature review: considerations in undertaking focus group research with culturally and linguistically diverse groups.
    Halcomb EJ; Gholizadeh L; DiGiacomo M; Phillips J; Davidson PM
    J Clin Nurs; 2007 Jun; 16(6):1000-11. PubMed ID: 17518876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness analyses alongside randomised clinical trials.
    Gray AM
    Clin Trials; 2006; 3(6):538-42. PubMed ID: 17170038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Costs of care in a mild-to-moderate Alzheimer clinical trial sample: key resources and their determinants.
    Gustavsson A; Cattelin F; Jönsson L
    Alzheimers Dement; 2011 Jul; 7(4):466-73. PubMed ID: 21784355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Determining optimal sample sizes for multistage adaptive randomized clinical trials from an industry perspective using value of information methods.
    Chen MH; Willan AR
    Clin Trials; 2013 Feb; 10(1):54-62. PubMed ID: 23263520
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The problem of protocol driven costs in pharmacoeconomic analysis.
    Coyle D; Lee KM
    Pharmacoeconomics; 1998 Oct; 14(4):357-63. PubMed ID: 10344904
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.